10 Best Supermarket Stocks To Buy For 2015

10 Best Supermarket Stocks To Buy For 2015: Idenix Pharmaceuticals Inc.(IDIX)

Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral diseases in the United States and Europe. Its primary research and development focus is on the treatment of patients with hepatitis C virus (HCV). The company?s HCV discovery program focuses on various classes of drugs, including nucleoside/nucleotide polymerase inhibitors, protease inhibitors, non-nucleoside polymerase inhibitors, and NS5A inhibitors. It develops products and drug candidates for the treatment of patients with hepatitis B virus (HBV), human immunodeficiency virus (HIV) type-1, and acquired immune deficiency syndrome (AIDS). The company principally has a collaboration agreement with Novartis Pharma AG for the development and commercialization of telbivudine, a drug for the treatment of HBV under the Tyzeka/Sebivo names. Idenix Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Advisors' Opinion:

• [By John Udovich]

  Small cap hepatitis stock Achillion Pharmaceuticals, Inc (NASDAQ: ACHN) saw shares jump on Monday only to then have a minor implosion on Tuesday – meaning its worth taking a look at that hiccup and the history of hiccups or successes from other small cap hepatitis stocks like Idenix Pharmaceuticals Inc (NASDAQ: IDIX), Arrowhead Research Corp (NASDAQ: ARWR) and Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY). It should be mentioned that Hepatitis A, B and C are viral infections that together affect an estimated 5% to 6% of Americans and while globally, 2 billion people (1 out of 3 people) have been infected with hepatitis B with  400 million people chronically infected plus 130–150 million people have chronic hepatitis C - meaning there is plenty of room for large and small cap p! layers alike in the space.

• [By Ben Levisohn]

  Bottom line from the Gilead standpoint for us is the Johnson & Johnson for Alios transaction is particularly interesting for 1) its RSV candidate to watch, 2) longer-term Alios has two nukes going into the clinic. 3) whether this has any read-through into companies that still might be interested in Achillion’s (ACHN) Phase I nuke program which will have data this fall and investors expect that to be acquired too since there were multiple bidders for Idenix Pharmaceuticals (IDIX). 4) This may also suggest if Johnson & Johnson continues development of these nukes that there is still a long tail for HCV if they want to invest in this for a drug that would be on the market out in 2018.

source from Top Stocks For 2015:http://www.topstocksblog.com/10-best-supermarket-stocks-to-buy-for-2015-2.html